Default company panoramic image
Logo

Izumi Biosciences LLC

Izumi develops oral fixed dose combinations to deliver FDA approved drugs to serious, orphan brain diseases that lack effective treatments

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lexington, MA, USA
  • Currency USD
  • Founded November 2011
  • Employees 2

Company Summary

Izumi’s IND-stage product, with patent protection until 2033, combines: 1. reformulated elacridar, a clinical stage penetration enhancer, and 2. imatinib, an FDA approved molecularly targeted therapeutic. The product crosses the blood-organ barrier to treat patients with neurofibromatosis type-1 (NF1). An FDA approved product will offset high direct costs, be prescribed by specialists, and reimbursed by insurers.

Team

  • Default avatar
    Ton (Antonius) Bunt
    President & CEO

    Ton is an MD PhD, who led a biotech turnaround, with a new strategic plan, and financing. He completed six licensing and M&A transactions with over $1B in cumulative value. As head of R&D at specialty pharma companies, he achieved clinical and regulatory milestones, incl. a Special Protocol Assessment with FDA, pivotal studies, and sNDA approvals. Product development, marketing, and leadership experience at Novartis in Europe and Merck in the US.

  • Default avatar
    Robert Anderson
    General counsel & CBO

    Bob is both a CPA and corporate lawyer with extensive international experience in technology transfer, licensing, collaborative research and clinical trial agreements and mergers and acquisitions, most recently at Abbott Laboratories. As General Counsel for BASF Bioresearch, Bob was a key player in acquiring, protecting and developing Knoll’s drug HUMIRA®, and orchestrated the $6.9 Billion acquisition of Knoll AG by Abbott.

Advisors

  • Default avatar
    Robert Anderson
    Lawyer
    Unconfirmed
    Default avatar
    Robert Bonavito
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Maarten Bunt
    Unconfirmed
    Default avatar
    Antonius M. (Ton) Bunt
    Unconfirmed